Publication: Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections
Issued Date
2006-06-15
Resource Type
ISSN
10584838
DOI
Other identifier(s)
2-s2.0-33744831964
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical Infectious Diseases. Vol.42, No.12 (2006), 1726-1734
Suggested Citation
Issam I. Raad, John R. Graybill, Ana Beatriz Bustamante, Oliver A. Cornely, Veronica Gaona-Flores, Claude Afif, Donald R. Graham, Richard N. Greenberg, Susan Hadley, Amelia Langston, Ricardo Negroni, John R. Perfect, Punnee Pitisuttithum, Angela Restrepo, Gary Schiller, Lisa Pedicone, Andrew J. Ullmann Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clinical Infectious Diseases. Vol.42, No.12 (2006), 1726-1734. doi:10.1086/504328 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/23723
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections
Other Contributor(s)
University of Texas MD Anderson Cancer Center
University of Texas Health Science Center at San Antonio
Springfield Clinic
University of Kentucky Chandler Medical Center
Tufts Medical Center
Emory University Hospital
Duke University School of Medicine
David Geffen School of Medicine at UCLA
Merck & Co., Inc.
Hospital Nacional Cayetano Heredia
Instituto Mexicano del Seguro Social
Hospital de Infecciosas Francisco Javier Muniz
Clinica Cardiovascular Colombiana
Mahidol University
University of Cologne
Johannes Gutenberg Universitat Mainz
University of Texas Health Science Center at San Antonio
Springfield Clinic
University of Kentucky Chandler Medical Center
Tufts Medical Center
Emory University Hospital
Duke University School of Medicine
David Geffen School of Medicine at UCLA
Merck & Co., Inc.
Hospital Nacional Cayetano Heredia
Instituto Mexicano del Seguro Social
Hospital de Infecciosas Francisco Javier Muniz
Clinica Cardiovascular Colombiana
Mahidol University
University of Cologne
Johannes Gutenberg Universitat Mainz
Abstract
Background. Invasive fungal infections are found most frequently in immunosuppressed and critically ill hospitalized patients. Antifungal therapy is often required for long periods. Safety data from the clinical development program of the triazole antifungal agent, posaconazole, were analyzed. Methods. A total of 428 patients with refractory invasive fungal infections (n = 362) or febrile neutropenia (n = 66) received posaconazole in 2 phase II/III open-label clinical trials. Also, 109 of these patients received posaconazole therapy for ≥6 months. Incidences of treatment-emergent, treatment-related, and serious adverse events and abnormal laboratory parameters were recorded during these studies. Results. Treatment-emergent, treatment-related adverse events were reported in 38% of the overall patient population. The most common treatment-related adverse events were nausea (8%) and vomiting (6%). Treatment-related serious adverse events occurred in 8% of patients. Low rates of treatment-related corrected QT interval and/or QT interval prolongation (1%) and elevation of hepatic enzymes (2%) were reported as adverse events. Treatment-emergent, treatment-related adverse events occurred at similar rates in patients who received posaconazole therapy for <6 months and ≥6 months. Conclusions. Prolonged posaconazole treatment was associated with a generally favorable safety profile in seriously ill patients with refractory invasive fungal infections. Long-term therapy did not increase the risk of any individual adverse event, and no unique adverse event was observed with longer exposure to posaconazole. © 2006 by the Infectious Diseases Society of America. All rights reserved.